###### Strengths and limitations of this study

-   Two consecutive viral load measurements were considered, avoiding misclassification of HIV treatment failure.

-   It was impossible to include clients' primary data.

-   Despite the recommendation of dolutegravir-based regimen for first-line therapy, its use has not started during the study period and was therefore not considered.

-   The analysis was not corrected for non-nucleoside reverse transcriptase inhibitor-based regimen independently.

Background {#s1}
==========

The prognosis for people with HIV has considerably improved since the introduction of highly active antiretroviral therapy (HAART) in 1996.[@R1] The preferred first-line regimen for adults and adolescents is TDF (Tenofovir Disoproxil Fumaratev)+3TC (Lamivudine)+DTG (dolutegravir) or TDF+3TC+EFV (Efavirenz) as a once-daily dose. However, in Ethiopia the use of DTG-based regimen has not started during this study period. Therefore once-daily regimens comprising nucleoside reverse transcriptase inhibitors backbone (TDF+3TC) and one non-nucleoside reverse transcriptase inhibitor (EFV) are being used as the preferred choice in adults.[@R3] To ensure successful treatment, monitoring of patients on antiretroviral therapy (ART) should start from the day of initiation.[@R5] The WHO immunological criteria for monitoring of response to ART have low sensitivity and positive predictive value in detecting treatment failure. Therefore, relying on CD4 counts for treatment monitoring would lead to misclassifications of treatment failure, which could result in unnecessary or delayed switch to second-line ART.[@R6] Viral load monitoring is important to avoid these misclassifications, the problem of switching to second-line ART and the risk of drug resistance.[@R7] Monitoring the level of HIV RNA to confirm appropriate response to treatment and durable viral suppression is the most accurate and meaningful measure of ART effectiveness.[@R9] It is the gold standard for identification of treatment failure in patients on ART, and since 2013 WHO has recommended it as the preferred monitoring approach to diagnose and confirm antiretroviral (ARV) treatment failure. Viral load should be monitored routinely at 6 months, at 12 months and every 12 months thereafter.[@R5] Virological failure is defined by a persistently detectable viral load exceeding 1000 copies/mL (ie, two consecutive viral load measurements within a 3-month interval, with adherence support between measurements) after at least 6 months of starting a new ART regimen.[@R6] Virological failure can occur for many reasons, such as patient adherence-related factors (missed clinic appointments, high pill burden and/or dosing frequency) and regimen-related factors (suboptimal pharmacokinetics, reduced efficacy due to prior exposure to suboptimal regimens).[@R11]

Increasing and monitoring the capacity for viral load testing are important measures for the global control of HIV, particularly in Sub-Saharan Africa, which has the highest prevalence of HIV worldwide.[@R12] Studies suggest that around 70% of patients on first-line ART who have a first high viral load will be virally suppressed following an adherence intervention, indicating non-adherence as the reason for the high viral load in majority of cases.[@R6] The UNAIDS (Joint United Nations Programme on HIV and AIDS) targets that 90% of people receiving ART would be virally suppressed by 2020.[@R13] However, surveys reveal that only 32.4% of people living with HIV (PLHIV) have viral suppression.[@R14] Currently, in Ethiopia, 1.5% of patients are on second-line ART regimens due to first-line treatment failure.[@R15] According to a study in Felegehiwot Referral Hospital in Amhara Region, since HAART was started, 51.1% of study participants have encountered virological failure within 6--48 months.[@R16] The prevalence of virological failure was 11.5% and 10.7% in studies conducted in Tigray and Amhara regions, respectively.[@R16]

Previously, targeted virological testing was adopted in Ethiopia for ART clients who have failed clinically and immunologically. However, following WHO recommendation, routine viral load testing has been practised since 2016. Currently, a significant number of clients have been experiencing virological failure and have switched to second-line treatment. Additionally, in 2018, viral load testing was integrated as one of ten weekly reportable diseases/events in Amhara Public Health Institute. Despite all these, the reasons for virological failure remain unclear.[@R5] Existing studies were conducted before the launch of routine viral load testing, and therefore have not explored the current situation of existing routine viral load testing.[@R17] Taking consecutive viral load measurements would be a better strategy to determine virological failure, compared with a single measurement which may lead to misclassification of HIV treatment failure.[@R19] However, previous studies took only a single virological test to identify virological failure. Hence, addressing this knowledge gap will help healthcare providers, local administrators, public health planners, policymakers and partners to plan and design appropriate intervention strategies. Patients who are at risk for virological failure can be identified early and prevention strategies can be implemented accordingly. In turn patients will get quality service and care, resulting in sustained HIV viral suppression and contributing to restoring their immune function with improvements in clinical well-being and reducing mortality and HIV transmission at the community level.

Methods and materials {#s2}
=====================

Study area and period {#s2-1}
---------------------

The town of Kombolcha is one of the 21 districts in South Wollo Zone in Amhara Region. It is 23 km away from the zonal town of Dessie, 503 km from Bahir Dar and 377 km from Addis Ababa. There are six health posts, four government health centres and ten private clinics, with two health centres providing ART service. According to the information obtained from ART clinics in November 2018, about 7178 PLHIV were ever enrolled in ART care. Out of these, 5327 ever started ART and 4128 were currently on HAART. The study was conducted from April to May 2019.

Study design and population {#s2-2}
---------------------------

An institution-based, unmatched, case--control study was conducted. The study population consisted of all adults living with HIV on first-line ART for 6 months or more before the first viral load test, followed at public health facilities in the town of Kombolcha and had their viral load tested from October 2016 to October 2018. All adults living with HIV on first-line ART for 6 months or more before the first viral load test who had documented viral load test results of \>1000 copies/mL with two consecutive measurements in a 3-month interval were included as cases, whereas those who had documented viral load test results of ≤1000 copies/mL were included as controls. Similarly, adults living with HIV on first-line ART for 6 months or more before the first viral load test whose one or both test results were not documented on the high viral load register were excluded from the cases, whereas test results that were not documented on routine viral load register were excluded from the controls.

Study variables {#s2-3}
---------------

Virological failure was the outcome variable of this study. Sociodemographic characteristics (age, sex, residency, educational level, occupation, marital status and religion), clinical and behavioural factors (nutritional status, functional status, WHO clinical stage, presence of Opportunistic Infections (OIs) and disclosure status), drug-related factors (original first-line ART regimen, change of ARV regimen or individual drug, current ART regimen at the time of viral load test, adherence, duration on ART, cotrimoxazole preventive therapy use, frequency of ART treatment per day and dispensed dose (number of pills) per day), and haematological factors (haemoglobin and CD4 count) were predictor variables.

Sample size determination {#s2-4}
-------------------------

Sample size was determined using Epi Info V.7 StatCalc. The assumptions made for the sample size calculation were 95% CI, 80% power and a case to control ratio of 1:2. Sample size was calculated by taking the key predictor of virological failure (immunological failure) from a previous study.[@R16] Therefore, the calculated sample size was 353 (118 cases and 235 controls). To compensate for those with incomplete records, 10% was added to the calculated sample size. Therefore the final calculated sample size came at 389 (130 cases and 259 controls), all of which participated in the study.

Sampling methods and procedures {#s2-5}
-------------------------------

Two health centres provide ART treatment and care services in the town of Kombolcha. From these health centres, all medical record numbers of clients who had tested for viral load from October 2016 to October 2018 were taken from routine and high viral load registers as virologically suppressed and failed, using code for both health centres. About 1919 HIV-infected adults who had suppressed viral load and 135 virologically failed adults living with HIV had switched to a second-line regimen. From virologically failed clients 130 cases and from all virologically suppressed clients 259 controls were selected using a computer-generated simple random sampling method. Finally a total of 389 clients were included in the study.

Data collection tools and procedures {#s2-6}
------------------------------------

Data were extracted from the charts of patients using a structured checklist. All available data from patient intake forms, WHO patient follow-up charts and viral load test registers containing detailed information on patients were reviewed for the selected cases and controls. Sociodemographic characteristics and clinical and laboratory data (haemoglobin and CD4^+^ count) were collected from the chart of each study participant. Data were collected by four ART trained health professionals with one supervisor.

Data quality assurance {#s2-7}
----------------------

Before starting the actual data collection, 1-day training was given to the data collectors and the supervisor. The checklist was reviewed and checked for completeness by the supervisor and the principal investigator. The principal investigator and the supervisor closely monitored the whole data collection process daily, with the provision of necessary feedback.

Data processing and analysis {#s2-8}
----------------------------

Data were checked for completeness, entered into Epi Info V.7, cleaned and exported to SPSS V.20 for analysis. For descriptive statistics, frequencies were used to describe the demographic, clinical, medication and haematological characteristics of patients. Bivariable logistic regression was carried out for all independent variables with an outcome variable. To identify candidate variables for multivariable logistic regression analysis, factors with p\<0.2 at bivariable logistic regression analysis were selected. Hosmer-Lemeshow goodness of fit test was used to check the model. Finally, independent variables that have a significant association with virological failure were identified based on adjusted OR (AOR), 95% CI and p\<0.05.

Patient and public involvement {#s2-9}
------------------------------

There were no patients involved in this study.

Results {#s3}
=======

Sociodemographic characteristics {#s3-1}
--------------------------------

A total of 389 participants (130 cases and 259 controls) were included in the study. The mean age of cases and controls was 31.6 years (SD ±10.72) and 36.6 years (SD ±9.48), respectively. Seventy-nine (60.8%) and 160 (61.8%) cases and controls were women. Ninety-nine (76.2%) and 170 (65.6%) cases and controls follow Muslim religion, respectively. Ninety-nine (76.2%) cases and 203 (78.4%) controls were living in rural areas. Fifty-one (39.2%) cases and 130 (50.2%) controls were married. Sixty-four (49.2%) cases and 121 (46.7%) controls attended primary education. Fifty-one (39.2%) and 75 (29%) cases and controls were not employed ([table 1](#T1){ref-type="table"}).

###### 

Sociodemographic characteristics of HIV-infected patients on first-line HAART at Kombolcha town health facilities, 2019

  Variables              Case, n (%)   Control, n (%)
  ---------------------- ------------- ----------------
  Sex                                  
   Male                  51 (39.2)     99 (38.2)
   Female                79 (60.8)     160 (61.8)
  Age                                  
   \<35 years            79 (60.8)     105 (40.5)
   ≥35 years             51 (39.2)     154 (59.5)
  Religion                             
   Muslim                99 (76.2)     170 (65.6)
   Others                31 (23.8)     89 (34.4)
  Residency                            
   Rural                 99 (76.2)     203 (78.4)
   Urban                 31 (23.8)     56 (21.6)
  Marital status                       
   Married               51 (39.2)     130 (50.2)
   Never married         41 (31.5)     62 (23.9)
   Divorced/separated    32 (24.6)     42 (16.2)
   Widowed               6 (4.6)       25 (9.7)
  Level of education                   
   Not educated          53 (40.8)     84 (32.4)
   Primary               64 (49.2)     121 (46.7)
   Secondary/tertiary    13 (10)       54 (20.8)
  Occupation                           
   Government employee   8 (6.2)       41 (15.8)
   Not employed          51 (39.2)     75 (29)
   Farmer                39 (30)       40 (15.4)
   Daily labourer        18 (13.8)     48 (18.5)
   Housewife             5 (3.8)       30 (11.6)
   Others                9 (6.9)       25 (9.7)
  Level of education                   
   No education          53 (40.8)     84 (32.4)
   Primary               64 (49.2)     121 (46.7)
   Secondary/tertiary    13(10)        54 (20.8)

HAART, highly active antiretroviral therapy.

Clinical and behavioural characteristics {#s3-2}
----------------------------------------

Among 389 participants (130 cases and 259 controls), 74 (56.9%) cases and 226 (87.3%) controls disclosed their HIV status to their families. One hundred and four (80%) cases and 242 (93.4%) controls had working functional status. Moreover 55 (42.3%) and 72 (27.8%) cases and controls had WHO stage III and IV at baseline, respectively. Fifty (38.5%) cases and 64 (24.7%) controls had undernutrition at baseline. Ninety-two (70.8%) and 109 (42.1%) cases and controls had missed their clinic visit in the last 6 months before the viral load test. Twenty-eight (21.5%) cases and 25 (9.7%) controls experienced opportunistic infections during the last 6 months of their treatment period ([table 2](#T2){ref-type="table"}).

###### 

Clinical and behavioural characteristics of HIV-infected patients on first-line HAART at Kombolcha town health facilities, 2019

  Variables                                  Case, n (%)   Control, n (%)
  ------------------------------------------ ------------- ----------------
  Disclosure status                                        
   Yes                                       74 (56.9)     226 (87.3)
   No                                        56 (43.1)     33 (12.7)
  Baseline functional status                               
   Working                                   104 (80)      242 (93.4)
   Ambulatory                                26 (20)       17 (6.6)
  Current functional status                                
   Working                                   123 (94.6)    253 (97.7)
   Ambulatory                                7 (5.4)       6 (2.3)
  Baseline WHO stage                                       
   Stage I and II                            75 (57.7)     187 (72.2)
   Stage III and IV                          55 (42.3)     72 (27.8)
  Current WHO stage                                        
   T stage I and II                          123 (94.6)    250 (96.5)
   T stage III and IV                        7 (5.4)       9 (3.5)
  Baseline nutritional status                              
   No undernutrition                         80 (61.5)     195 (75.3)
   Undernutrition                            50 (38.5)     64 (24.7)
  Current nutritional status                               
   No undernutrition                         98 (75.4)     231 (89.2)
   Undernutrition                            32 (24.6)     28 (10.8)
  Missed clinic visit in the last 6 months                 
   Yes                                       92 (70.8)     109 (42.1)
   No                                        38 (29.2)     150 (57.9)
  Number of missed clinic visits                           
   Once                                      14 (15.2)     40 (36.7)
   Twice or more                             78 (84.8)     69 (63.3)
  Time of missed clinic                                    
   In the last 3 months                      49 (53.3)     61 (56)
   In the last 3--6 months                   43 (46.7)     48 (44)
  History of OIs                                           
   Yes                                       28 (21.5)     25 (9.7)
   No                                        102 (78.5)    234 (90.3)

HAART, highly active antiretroviral therapy; OIs, opportunistic infections.

Antiretroviral drug and haematological characteristics {#s3-3}
------------------------------------------------------

While 47 (36.2%) cases started their ART treatment with stavudine (D4T)-based regimen, 130 (50.2%) controls were on TDF-based regimen. Fifty-seven (43.8%) and 94 (36.3%) cases and controls changed their original regimen, respectively. Eighty-nine (68.5%) cases and 131 (50.6) controls take their treatment twice daily. Ninety-nine (76.2%) cases and 201 (77.6%) controls were on ART for 48 months and more. Moreover 25 (19.2%) and 28 (10.8%) cases and controls had poor adherence to treatment, respectively. The baseline CD4 count of 94 (72.3%) cases and 150 (57.9%) controls was ≤250 cells/mm^3^. Similarly 66 (50.8%) and 55 (21.2%) cases and controls had a CD4 count of ≤250 cells/mm^3^ at the time of the viral load test, respectively. Fifty-eight (44.6%) cases and 74 (28.6%) controls had baseline haemoglobin of \<12 g/dL ([table 3](#T3){ref-type="table"}).

###### 

Antiretroviral drug and haematological characteristics of HIV-infected patients on first-line HAART at Kombolcha town health facilities, 2019

  Variables                                        Case, n (%)   Control, n (%)
  ------------------------------------------------ ------------- ----------------
  Original ART regimen                                           
   D4T-based                                       47 (36.2)     76 (29.3)
   ZDV-based                                       40 (30.8)     53 (20.5)
   TDF-based                                       43 (33.1)     130 (50.2)
  Change of ART                                                  
   Yes                                             57 (43.8)     94 (36.3)
   No                                              73 (56.2)     165 (63.7)
  Number of changes in ART                                       
   Once                                            50 (87.7)     84 (89.4)
   Twice or more                                   7 (12.3)      10 (10.6)
  Current ART regimen at the time of the VL test                 
   ZDV-based                                       62 (47.7)     71 (27.4)
   TDF-based                                       68 (52.3)     188 (72.6)
  Frequency of treatment                                         
   Once a day                                      41 (31.5)     128 (49.4)
   Twice a day                                     89 (68.5)     131 (50.6)
  Number of ART pills                                            
   One pill per day                                40 (30.8)     128 (49.4)
   Two pills per day                               45 (34.6)     51 (19.7)
   Three pills per day                             45 (34.6)     80 (30.9)
  Adherence                                                      
   Good                                            105 (80.8)    231 (89.2)
   Poor                                            25 (19.2)     28 (10.8)
  Duration on ART                                                
   6--23 months                                    9 (6.9)       13 (5)
   24--47 months                                   22 (16.9)     45 (17.4)
   ≥48 months                                      99 (76.2)     201 (77.6)
  Current CPT use during VL test                                 
   Yes                                             41 (31.5)     58 (22.4)
   No                                              89 (68.5)     201 (77.6)
  Baseline CD4 count                                             
   ≤250 cells/mm^3^                                94 (72.3)     150 (57.9)
   \>250 cells/mm^3^                               36 (27.7)     109 (42.1)
  Recent CD4 count                                               
   ≤250 cells/mm^3^                                66 (50.8)     55 (21.2)
   \>250 cells/mm^3^                               64 (49.2)     204 (78.8)
  Baseline Hgb                                                   
   \<12 g/dL                                       58 (44.6)     74 (28.6)
   ≥12 g/dL                                        72 (55.4)     185 (71.4)
  Recent Hgb                                                     
   \<12 g/dL                                       40 (30.8)     45 (17.4)
   ≥12 g/dL                                        90 (69.2)     214 (82.6)

ART, antiretroviral therapy; CPT, cotrimoxazole preventive therapy; D4T, Stavudine; HAART, highly active antiretroviral therapy; Hgb, haemoglobin; TDF, tenofovir; ZDV, Zidovudine.

Determinants of HIV virological failure {#s3-4}
---------------------------------------

After adjustment for possible effects of confounding variables, age, marital status, occupation, disclosure status, baseline functional status, missed clinic visit, current ART regimen, adherence to treatment and recent CD4 count were found significantly associated with virological failure.

The odds of HIV virological failure were 2.4-fold (AOR=2.44, 95% CI 1.353 to 4.411) higher in clients aged less than 35 years compared with older counterparts. The odds of virological failure in clients who had divorced or separated from their spouses were threefold (AOR=3.03, 95% CI 1.356 to 6.778) higher than of married clients. The odds of HIV virological failure were 4.7-fold (AOR=4.69, 95% CI 1.536 to 14.292) and eightfold (AOR=8.04, 95% CI 2.532 to 25.558) higher in clients who were not employed and farmers in occupation compared with government-employed clients, respectively.

The odds of virological failure were fivefold (AOR=5.00, 95% CI 2.596 to 9.630) higher in clients who did not disclose their HIV status compared with those who disclosed. Similarly the odds of virological failure were 2.7-fold (AOR=2.71, 95% CI 1.148 to 6.392) higher in clients who had ambulatory functional status at baseline compared with those who had working functional status. Moreover the odds of virological failure were 4.5-fold (AOR=4.512, 95% CI 2.438 to 8.350) higher in clients who had missed their clinic visit in the last 6 months before the viral load test compared with those who did not miss their clinic visit.

The odds of virological failure were threefold (AOR=2.99, 95% CI 1.333 to 6.734) higher in clients who had poor adherence to ART than those who had good adherence. Similarly the odds of virological failure were 2.6-fold (AOR=2.633, 95% CI 1.444 to 4.800) higher among clients who were on Zidovudine (ZDV)- based regimen during the viral load test than those who were on TDF-based regimen.

The odds of virological failure were 7.5-fold (AOR=7.51, 95% CI 3.985 to 14.140) higher in clients who had a recent CD4 count of ≤250 cells/mm^3^ compared with those with \>250 cells/mm^3^ ([table 4](#T4){ref-type="table"}).

###### 

Simple and multiple binary logistic regression analyses for determinants of virological failure among HIV-infected adults on HAART at Kombolcha town public health facilities, 2019

  Variables                                        Virological failure   COR (95% CI)   AOR (95% CI)              
  ------------------------------------------------ --------------------- -------------- ------------------------- ---------------------------
  Age                                                                                                             
   \<35 years                                      79 (60.8)             105 (40.5)     2.272 (1.477 to 3.495)    2.442 (1.353 to 4.411)\*
   ≥35 years                                       51 (39.2)             154 (59.5)     1                         1
  Religion                                                                                                        
   Muslim                                          99 (76.2)             170 (65.6)     1.672 (1.037 to 2.697)    1.153 (0.580 to 2.293)
   Orthodox                                        31 (23.8)             89 (34.4)      1                         1
  Marital status                                                                                                  
   Married                                         51 (39.2)             130 (50.2)     1                         1
   Never married                                   41 (31.5)             62 (23.9)      1.686 (1.012 to 2.808)    1.518 (0.767 to 3.002)
   Divorced/separated                              32 (24.6)             42 (16.2)      1.942 (1.107 to 3.408)    3.032 (1.356 to 6.778)\*
   Widowed                                         6 (4.6)               25 (9.5)       0.612 (0.237 to 1.579)    0.430 (0.128 to 1.442)
  Level of education                                                                                              
   Not educated                                    53 (40.8)             84 (32.4)      2.621 (1.306 to 5.258)    2.594 (0.916 to 7.349)
   Primary                                         64 (49.2)             121 (46.7)     2.197 (1.116 to 4.324)    2.078 (0.766 to 5.640)
   Secondary/tertiary                              13 (10)               54 (20.8)      1                         1
  Occupation                                                                                                      
   Government employee                             8 (6.2)               41 (15.8)      1                         1
   Unemployed                                      51 (39.2)             75 (29.0)      3.485 (1.509 to 8.048)    4.686 (1.536 to 14.292)\*
   Farmer                                          39 (30.0)             40 (15.4)      4.997 (2.080 to 12.006)   8.044 (2.532 to 25.558)\*
   Daily labourer                                  18 (13.8)             48 (18.5)      1.922 (0.757 to 4.877)    1.929 (0.572 to 6.503)
   Housewife                                       5 (3.8)               30 (11.6)      0.854 (0.254 to 2.872)    1.333 (0.296 to 6.010)
   Others                                          9 (6.9)               25 (9.7)       1.845 (0.630 to 5.403)    2.869 (0.735 to 11.207)
  Disclosure status                                                                                               
   No                                              56 (43.1)             33 (12.7)      5.183 (3.131 to 8.578)    5.000 (2.596 to 9.630)\*
   Yes                                             74 (56.9)             226 (87.3)     1                         1
  Baseline functional status                                                                                      
   Ambulatory                                      26 (20)               17 (6.6)       3.559 (1.852 to 6.838)    2.709 (1.148 to 6.392)\*
   Working                                         104(80)               242 (93.4)     1                         1
  Baseline WHO stage                                                                                              
   Stage III and IV                                55 (42.3)             72 (27.8)      1.905 (1.225 to 2.962)    1.350 (0.713 to 2.556)
   Stage I and II                                  75 (57.7)             187 (72.2)     1                         1
  Current nutritional status                                                                                      
   Acute undernutrition                            32 (24.6)             28 (10.8)      2.694 (1.539 to 4.714)    1.391 (0.602 to 3.211)
   No acute undernutrition                         98 (75.4)             231 (89.2)     1                         1
  Missed clinic visit in the last 6 months                                                                        
   Yes                                             92 (70.8)             109 (42.1)     3.332 (2.122 to 5.232)    4.512 (2.438 to 8.350)\*
   No                                              38 (29.2)             150 (57.9)     1                         1
  History of OIs in the last 6 months                                                                             
   Yes                                             28 (21.5)             25 (9.7)       2.569 (1.428 to 4.623)    1.279 (0.512 to 3.195)
   No                                              102 (78.5)            234 (90.3)     1                         1
  Original ART regimen                                                                                            
   D4T-based                                       47 (36.2)             76 (29.3)      1.870 (1.133 to 3.086)    1.366 (0.546 to 3.419)
   ZDV-based                                       40 (30.8)             53 (20.5)      2.282 (1.335 to 3.900)    0.983 (0.315 to 3.066)
   TDF-based                                       43 (33.1)             130 (50.2)     1                         1
  Current ART regimen at the time of the VL test                                                                  
   ZDV-based                                       62 (47.7)             71 (27.4)      2.341 (1.508 to 3.633)    2.633 (1.444 to 4.800)\*
   TDF-based                                       68 (52.3)             188 (72.6)     1                         1
  Frequency of treatment                                                                                          
   Twice per day                                   89 (68.5)             131 (50.6)     2.121 (1.362 to 3.303)    1.013 (0.031 to 33.261)
   Once per day                                    41 (31.5)             128 (49.4)     1                         1
  Number of ART pills                                                                                             
   One pill per day                                40 (30.8)             128 (49.4)     1                         1
   Two pills per day                               45 (34.6)             51 (19.7)      2.824 (1.653 to 4.823)    0.988 (0.026 to 37.997)
   Three pills per day                             45 (34.6)             80 (30.9)      1.800 (1.082 to 2.996)    1.220 (0.035 to 42.729)
  Adherence                                                                                                       
   Poor                                            25 (19.2)             28 (10.8)      1.964 (1.093 to 3.531)    2.996 (1.333 to 6.734)\*
   Good                                            105 (80.8)            231 (89.2)     1                         1
  Recent CD4 count                                                                                                
   ≤250 cells/mm^3^                                66 (50.8)             55 (21.2)      3.825 (2.427 to 6.028)    7.507 (3.985 to 14.140)\*
   \>250 cells/mm^3^                               64 (49.2)             204 (78.8)     1                         1
  Recent Hgb                                                                                                      
   \<12 g/dL                                       40 (30.8)             45 (17.4)      2.114 (1.292 to 3.457)    1.302 (0.653 to 2.596)
   ≥12 g/dL                                        90 (69.2)             214 (82.6)     1                         

The p value for Hosmer-Lemeshow goodness of fit test was found to be 0.087.

\*Variables with significant association during multiple binary logistic regression analysis.

AOR, adjusted OR; ART, antiretroviral therapy; COP, country operational plan; D4T, stavudine; HAART, highly active antiretroviral therapy; Hgb, haemoglobin; OIs, opportunistic infections; TDF, tenofovir; VL, viral load; ZDV, zidovudine.

Discussion {#s4}
==========

In this study virological failure was found to be significantly associated with age, marital status, occupation, disclosure status, baseline functional status, missed clinic visit, current ART regimen, adherence to treatment and recent CD4 count.

The odds of HIV virological failure were 2.4-fold higher in clients aged less than 35 years compared with older clients. This finding is similar to studies conducted in Tigray,[@R17] Gondar,[@R18] Uganda,[@R20] Mozambique,[@R21] Australia[@R22] and Latin America,[@R23] where younger patients had a higher risk of virological failure. This might be due to their vulnerability to emotional instability with depression, which leads to poor adherence resulting in poor treatment outcomes.[@R24] The odds of virological failure were threefold higher in clients who had divorced or separated from their spouses compared with those of married clients. The increased risk of virological failure might be due to failure to get care and support from her/his spouse in taking treatment and follow-up. However, a study conducted in Myanmar revealed that patients who were divorced or separated from their spouses had a significantly lower risk of failure.[@R25] The difference in findings might be due to the use of different viral load cut-off points for classification of virological failure. The odds of HIV virological failure were 4.7-fold and eightfold higher in clients who were not employed and farmers in occupation compared with government-employed clients, respectively. This finding is in line with the findings from China.[@R26] This might be due to differences in lifestyle, awareness of follow-up and drug-taking time, which could affect their adherence to treatment.

Clients should be counselled and encouraged to disclose their status to their sexual partners and others, to participate in peer support groups or to be a member of PLHIV associations.[@R5] This study showed that the odds of virological failure were fivefold higher in clients who did not disclose their HIV status to their families, compared with those who disclosed their HIV status. This finding agrees with the findings from Nigeria[@R27] and Tanzania,[@R28] which showed non-disclosure of HIV status increased the odds of virological failure. This might be due to failure in getting help or adherence support from families or PLHIV associations and the difficulty of taking their treatment on time.[@R5] Similarly the odds of virological failure were 2.7-fold higher in clients who had ambulatory functional status at baseline compared with those who had working functional status. This finding agrees with the findings from Bahir Dar[@R16] and Bale Zone,[@R29] where being ambulatory at baseline was found to be a significant risk factor for virological failure. Since patients' ability to perform routine activities related to advanced HIV disease and opportunistic infections, virological failure might be due to delayed start of treatment when the disease has progressed with high viral load or due to difficulty in properly attending follow-up.[@R30] Moreover, the odds of virological failure were 4.5-fold higher in clients who missed their clinic visit in the last 6 months before the viral load test, compared with those who did not miss their clinic visit. This finding is supported by the findings from Australia[@R22] and Myanmar,[@R25] where virological failure was associated with missed clinic appointments. This finding might be due to patients on ART missing their appointments and therefore more likely to miss their doses, resulting in poor adherence to treatment.

Treatment goals should be maximal and durable suppression of viral load, restoration and preservation of immunological function, improvement of quality of life, and reduction of HIV-related morbidity and mortality.[@R5] Rates of viral load decline towards undetectable are influenced by clients' adherence to the regimen.[@R19] This study showed that the odds of virological failure were threefold higher in clients who had poor adherence to ART compared with those who had good adherence. Similarly, studies conducted in Tigray,[@R17] Gondar,[@R18] Bahir Dar,[@R16] Mozambique,[@R17] Nigeria,[@R13] Uganda[@R21] and Tanzania[@R25] showed that poor adherence increased the odds of virological failure. This might be because poor adherence could allow periods of viral replication, leading to the development of drug resistance and resulting in limited treatment effectiveness.[@R31] Predictors of virological success also depend on high potency, tolerability and convenience of the ARV regimen.[@R31]

This study revealed that the odds of HIV virological failure were 2.6-fold higher in clients with ZDV-based regimen during the viral load test, compared with those who were on TDF-based regimen. This finding is in line with findings from a meta-analysis conducted in Ethiopia which showed superior viral load suppression of using TDF-based first-line regimen than ZDV-based regimen.[@R32] This might be because TDF-based regimens were more likely to be tolerated than ZDV-based regimens.[@R32] This might also be due to the high efficacy and lower level of toxicity of fixed-dose TDF-3TC compared with fixed-dose ZDV-3TC.[@R33] The 2018 Ethiopian consolidated ART guideline recommends the more tolerable DTG-based regimen for first-line therapy, which can improve adherence to treatment.[@R4]

The odds of virological failure were 7.5-fold higher in clients who had a recent CD4 count of ≤250 cells/mm^3^ compared with those with \>250 cells/mm^3^. This finding is in line with findings from Bahir Dar,[@R16] Tigray,[@R17] France,[@R34] Brazil,[@R35] Australia[@R22] and China.[@R26] This might be because a significant number of CD4 cells can respond to HIV antigens present on the surface of infected cells, which is associated with lower HIV viral loads, resulting in viral control.[@R36]

Since taking consecutive viral load measurements would be a better strategy to determine virological failure, compared with a single measurement, this study takes two consecutive viral load measurements, which avoid misclassification of HIV treatment failure. Since it was conducted at the health centre level, virologically failed clients were referred to different hospitals for a second-line regimen, which created difficulty in including primary data from clients. Despite the recommendation of DTG-based regimen for first-line therapy, its use has not started during the study period and was therefore not considered.

Conclusions and recommendations {#s5}
===============================

This study revealed that age, marital status, occupation, disclosure status, baseline functional status, missed clinic visit, current ART regimen, adherence to treatment and recent CD4 count were significantly associated with virological failure. Therefore, implementation of treatment and care strategies should consider younger clients, unemployed clients, farmers and divorced/separated clients to improve their treatment follow-up for better viral suppression. Adherence support should also be strengthened for clients who had poor adherence, and those who miss their clinic visits should be targeted to help them better adhere to treatment, and therefore help them boost their immunity and suppress viral replication. In addition to these, clients should be encouraged to disclose their HIV infection status to their families or supportive associations as this will help them get support. Chronic care and follow-up should also be strengthened by focusing on ambulatory clients at the start of their HAART, clients who have been taking ZDV-based regimens and clients with recent lower CD4 count.
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